• Jie Li, Yan Liu, Lin Li, Weijun Chen, Dujuan Xu, Aimei Xiao, Ling Ma, Wanxue Jiang, and Lijuan Yang.
• The Reproductive Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
• Medicine (Baltimore). 2024 Oct 25; 103 (43): e40210e40210.

AbstractTo evaluate whether RNA-seq-based endometrial receptivity testing (rsERT) can improve pregnancy outcomes in personalized frozen-thawed embryo transfer (pFET) during hormone replacement therapy (HRT) cycles among patients with recurrent implantation failure (RIF). We conducted a retrospective cohort study involving 98 RIF patients undergoing HRT for FET. The experimental group consisted of 58 patients who underwent pFET after rsERT, while the control group included 40 patients who refused rsERT and underwent conventional ET. We recorded and examined the subsequent pregnancy outcomes from all cycles. The results of rsERT revealed that 67.24% of the experimental group were out of the "window of implantation" (WOI), with all cases showing a delay. The HCG-positive rate, implantation rate, and clinical pregnancy rate (CPR) in the experimental group were significantly higher than those in the control group, at 75.86% versus 50.00% (P = .030), 56.38% versus 31.43% (P = .002), and 68.97% versus 47.50% (P = .033), respectively. Our study demonstrated that utilizing rsERT technology to guide pFET in HRT cycles significantly enhances implantation and CPRs in RIF patients. Importantly, our findings confirm the effectiveness of rsERT technology and establish a scientific rationale for personalized reproductive medical interventions.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

14 keywords...

hide…